Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Thermo Fisher Scientific to Acquire Clario Holdings in $8.9 Billion Deal

Thermo Fisher Scientific to Acquire Clario Holdings in $8.9 Billion Deal

Thermo Fisher Scientific, a leading player in the pharmaceutical and biotechnology industry, has announced a significant acquisition that is set to reshape the landscape of clinical trial data management. The company will acquire Clario Holdings, a prominent clinical trial data firm, for $8.9 billion in cash, with additional performance-based payments potentially reaching $525 million.

NoahAI News10/30/2025
Lilly Expands Access to Obesity Drug Zepbound Through Walmart Partnership

Lilly Expands Access to Obesity Drug Zepbound Through Walmart Partnership

Eli Lilly has announced a strategic partnership with Walmart to broaden access to its obesity medication Zepbound, marking a significant development in the pharmaceutical giant's direct-to-consumer initiatives. The collaboration, set to launch in mid-November, will allow patients to pick up Zepbound orders placed through Lilly's online service at Walmart pharmacies, offering a discounted cash-pay option that bypasses traditional insurance channels.

NoahAI News10/30/2025
Novartis Reports Promising Phase 3 Results for Sjögren's Syndrome Drug Ianalumab

Novartis Reports Promising Phase 3 Results for Sjögren's Syndrome Drug Ianalumab

Novartis has unveiled encouraging results from two phase 3 clinical trials evaluating ianalumab, its investigational monoclonal antibody for the treatment of Sjögren's syndrome. The studies, known as Neptunus-1 and Neptunus-2, mark a significant milestone in the development of potential therapies for this autoimmune disease, which currently lacks approved systemic treatments.

NoahAI News10/30/2025
Merck and Eisai Face Setback in Liver Cancer Treatment as Keytruda-Lenvima Combination Fails to Meet Survival Endpoint

Merck and Eisai Face Setback in Liver Cancer Treatment as Keytruda-Lenvima Combination Fails to Meet Survival Endpoint

Merck & Co. and Eisai have announced the discontinuation of their phase 3 LEAP-012 study, evaluating the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) in patients with unresectable, non-metastatic hepatocellular carcinoma (HCC). The decision comes after the treatment failed to demonstrate a statistically significant improvement in overall survival when added to transarterial chemoembolization (TACE), compared to TACE alone.

NoahAI News10/30/2025
Akebia Therapeutics Halts Plans for Vafseo Trial Expansion

Akebia Therapeutics Halts Plans for Vafseo Trial Expansion

Akebia Therapeutics has announced the discontinuation of its planned clinical trial aimed at expanding the patient population for its anemia drug Vafseo. This decision comes after discussions with the U.S. Food and Drug Administration (FDA) failed to reach an agreement on the study design.

NoahAI News10/30/2025
UHS Raises Revenue Guidance for 2025 Amid Strong Acute Care Performance

UHS Raises Revenue Guidance for 2025 Amid Strong Acute Care Performance

Universal Health Services (UHS), a major for-profit healthcare operator, has increased its financial forecast for 2025 following a robust third-quarter performance. The company's strategic moves in acute care and recent regulatory developments have contributed to its positive outlook, despite ongoing challenges in its behavioral health division.

NoahAI News10/30/2025
Regeneron and ModeX Therapeutics Forge $1B+ Antibody Development Partnership

Regeneron and ModeX Therapeutics Forge $1B+ Antibody Development Partnership

Regeneron Pharmaceuticals has entered into a significant collaboration with ModeX Therapeutics, pledging over $1 billion in potential payments to leverage ModeX's next-generation antibody platform. This partnership marks a substantial investment in the development of multispecific antibodies, aiming to address a range of diseases including immunology, oncology, and metabolic disorders.

NoahAI News10/30/2025
GSK Upholds £40B Sales Target for 2031 as Leadership Transition Approaches

GSK Upholds £40B Sales Target for 2031 as Leadership Transition Approaches

GSK, the British pharmaceutical giant, has reaffirmed its ambitious £40 billion sales target for 2031, despite skepticism from some analysts. This announcement came during Emma Walmsley's final quarterly report as CEO, setting a positive tone for the upcoming leadership transition to Luke Miels on January 1, 2026.

NoahAI News10/30/2025
Argenx's Vyvgart Shows Promise in Seronegative Myasthenia Gravis Patients, Expanding Treatment Options

Argenx's Vyvgart Shows Promise in Seronegative Myasthenia Gravis Patients, Expanding Treatment Options

Argenx, a leading pharmaceutical company in the field of autoimmune diseases, has unveiled promising results from its ADAPT SERON trial, demonstrating the efficacy of its blockbuster drug Vyvgart (efgartigimod) in seronegative generalized myasthenia gravis (gMG) patients. This development marks a significant step forward in addressing the unmet needs of a subset of gMG patients who have long been overlooked in the treatment paradigm.

NoahAI News10/30/2025
Novartis Leads Pharma M&A Surge with $12B Avidity Acquisition

Novartis Leads Pharma M&A Surge with $12B Avidity Acquisition

Novartis has made waves in the pharmaceutical industry with its $12 billion acquisition of Avidity Biosciences, marking the second-largest deal of the year. The Swiss pharma giant announced the purchase on Sunday, signaling a growing trend of increased M&A activity in the sector. This move follows Johnson & Johnson's acquisition of Intra-Cellular earlier in the year, which remains the largest deal to date.

NoahAI News10/30/2025
Kyverna's CAR-T Therapy Shows Promise in Autoimmune Disease Trial

Kyverna's CAR-T Therapy Shows Promise in Autoimmune Disease Trial

Kyverna Therapeutics has reported encouraging results from a small-scale trial of its CAR T-cell therapy, KYV-101, in patients with generalized myasthenia gravis (gMG). The phase 2 data suggest that the treatment could offer significant benefits for those with moderate to severe autoimmune conditions who have not responded to existing therapies.

NoahAI News10/30/2025
Tenet Healthcare Raises 2025 Forecast, Boosts Investment in High-Acuity Services

Tenet Healthcare Raises 2025 Forecast, Boosts Investment in High-Acuity Services

Tenet Healthcare, a major hospital operator, has raised its full-year financial forecast for 2025 and announced plans to increase capital expenditure, focusing on high-acuity service lines and organic hospital growth. The company's third-quarter results, released on Tuesday, showed year-over-year growth in revenue and adjusted earnings, prompting the second consecutive quarterly forecast upgrade.

NoahAI News10/30/2025
«1...121314...67»